This trial studies an investigational medication injected into tumors and affected lymph nodes for stage 3 non-small cell lung cancer in participants that are not eligible for surgery. All participants receive radiation and chemotherapy, and some may later receive immunotherapy. Two thirds of participants are randomized to also receive the investigational medication.
The goal of this clinical trial is to test how well the investigational medication works to stop or slow your cancer when used with the standard therapy, compared to the standard therapy alone.
Non-small cell lung cancer is a type of cancer in the tissue of the lungs. It is the most common type of lung cancer.
During the clinical trial, all participants will receive the standard chemotherapy with radiation therapy. Depending on how your disease responds, some participants may also receive immunotherapy, a type of medication approved for lung cancer. Your treatments will be coordinated by a physician team that may include an interventional pulmonologist, thoracic surgeon, interventional radiologist, radiation oncologist, and medical oncologist. There is a 2 in 3 (approximately 67%) chance you will be randomly assigned to a group that also receives the investigational medication. This random assignment helps researchers compare the three groups fairly and avoid bias.
The investigational medication is a liquid containing microscopic drug particles that is injected directly into the tumor and/or affected lymph nodes. This injection most often occurs in an operating or procedure room and will be performed by a trial doctor (for example, an interventional pulmonologist, interventional radiologist, or a trial doctor trained in lung/lymph node injections). The trial doctor will use conscious sedation or general anesthesia, and local anesthesia if needed. They will discuss which type is appropriate for your specific procedure.
See if you may qualify
Answer the following questions to see if you or someone you know may be eligible to take part in this study.
Please keep in mind:
Even if you believe you meet the eligibility criteria, joining a clinical trial is not guaranteed. Whether you’re referred or able to take part depends on a review by a qualified healthcare professional.
Note about privacy: Email responses may not be encrypted. This means there’s a chance that messages could be seen by someone other than the intended recipient. We will avoid including sensitive personal information in emails whenever possible. However, we cannot guarantee that no sensitive information will be revealed indirectly.
About your information:
With your consent, we will use your answers to help determine whether you may be eligible for this clinical trial. You can withdraw your consent at any time.
Your information may be transferred to countries outside your country of residence, including the United States, which may have different data protection rules.
If you submit any personal information about someone else, you confirm that you have permission to do so.
Please read our Privacy policy for more details.